Skip to main content

Table 2 Plasma levels of M-CSF, CA 125 and HE4 in tested groups

From: M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients

  Groups M-CSF HE4 CA 125
(pg/ml) (pmol/L) (U/ml)
Ovarian cancer Median Range stage I 1 1/2 1
444.40 83.54 63.62
159.80 -2702.20 27.50-1093.80 12.50-650.4 0
stage II 1/2 1/2 1/2
619.76 62.64 61.62
221.70-1764.00 24.00-625.10 8.40-998.00
stage III 1/2/4 1/2/4 1/2/4
706.45 117.92 766.84
200.05-3791.05 47.00-1500.00 9.84-2060.78
stage IV 1/2/4 1/2/4 1/2/4
1009.40 198.14 531.92
235.64-2091.75 36.40-1944.20 13.64-8602.30
Total group 1/2 1/2 1/2
633.00 103.64 133.39
159.80-3791.05 24.00-1944.20 8.40-8602.30
Serous epithelial 1/5/6/7 1/5/6/7 1/5/6/7
794.05 126.24 171.24
221.7-3791.05 28.60-1944.20 8.40-8602.30
Endometrioid epithelial 1/6 1/6/7 1/6/7
606.48 68.50 114.24
159.80-3396.20 24.00-1740.00 10.92-1425.00
Control groups Median Range Benign ovarian tumor Cystis endometrioides 3 3 3/8
434.28 23.18 43.44
125.30-2209.30 14.00-68.60 7.50-2748.00
Cystis serous 3 8 3
468.35 43.34 20.69
166.90-1604.40 25.40-159.94 5.40-451.80
Total group 3   3
448.10 42.60 27.74
125.30-2209.30 14.00-159.94 5.40-2748.00
Healthy subjects 298.55 44.32 10.02
119.63-1097.00 6.20-122.30 5.06-36.60
  1. 1statistically significant when comparing EOC patients with healthy subjects.
  2. 2statistically significant when comparing EOC patients with benign ovarian tumor total group.
  3. 3statistically significant when comparing patients with benign ovarian tumor and healthy subjects.
  4. 4statistically significant when comparing EOC patients in stage III or IV with stage I or II.
  5. 5statistically significant when comparing EOC patients i.e. sub-type serous with sub-type endometrioid.
  6. 6statistically significant when comparing with benign ovarian tumor group i.e. type cystis endometrioides.
  7. 7statistically significant when comparing with benign ovarian tumor group i.e. type cystis serous.
  8. 8statistically significant when comparing patients with benign ovarian tumor i.e. type cystis endometrioides with type cystis serous.